Different trends of p53, MDM2 and p14ARF expression patterns in endometrial adenocarcinomas versus hyperplasia

Experimental Oncology

Volumn 29, Issue 4, 2007, Pages 287-294

  Buchynska, L G ^a   Nesina, I P ^a   Kashuba, E V ^b  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Endometrial cancer; MDM2; p14ARF expression; p53

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADENOCARCINOMA; ADULT; AGED; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 39049084302     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Hanf V, Gunthert AR, Emons G. Endometrial cancer. Onkologie 2003; 26: 429-36.
2. Fedorenko ZP, Gulak LO, Goroh EL, et al. Cancer in Ukraine, 2003-2004. Morbility, mortality, indicators of oncological services activity. Bull Nat Cancer Register Ukraine. Kyiv: 2005; 97 p. (in Ukrainian).
3. Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol 2004; 35: 649-62.
4. Maeda K, Tsuda H, Hashiguchi Y, et al. Relationship between p53 pathway and estrogen receptor status in endometrioid-type endometrial cancer. Hum Pathol 2002; 33: 386-91.
5. Cinel L, Polat A, Aydin O, et al. Bcl-2, iNOS, p53 and PCNA expression in normal, disordered proliferative, hyperplastic and malignant endometrium. Pathol Int 2002; 52: 384-9.
6. Ohkouchi T, Sakuragi N, Watari H, et al. Fujimoto S. Prognostic significance of Bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinoma. Am J Obstet Gynecol 2002; 187: 353-9.
7. Elhafey AS, Papadimitriou JC, El-Hakim MS, et al. Computerized image analysis of p53 and proliferating cell nuclear antigen expression in benign, hyperplastic, and malignant endometrium. Arch Pathol Lab Med 2001; 125: 872-9.
8. Ambros RA, Sheehan CE, Kallakury BV, et al. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma. Mod Pathol 1996; 9: 1165-9.
9. Brys M, Semczuk A, Wojcik M, et al. p53 protein detection by the western blotting technique in normal and neoplastic specimens of human endometrium. Cancer Lett 2000; 148: 197-205.
10. Sakuragi N, Watari H, Ebina Y, et al. Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer. Int J Cancer 2005; 116: 514-9.
11. Stewart RL, Royds JA, Burton JL, et al. Direct sequencing of the p53 gene shows absence of mutations in endometrioid endometrial adenocarcinomas expressing p53 protein. Histopathology 1998; 33: 440-5.
12. Sakuragi N, Hirai A, Tada M, et al. Dominant negative mutation of p53 tumor suppressor gene in endometrial carcinoma. Gynecologic Oncology 2001; 83: 485-90.
13. Kopnin BP. Tumor suppressor and mutator genes. In: Cancerogenesis. DG Zaridze, ed. Moskow: Medicine, 2004; 576 p (in Russian).
14. Pijnenborg JM, van de Broek L, Dam de Veen GC, et al. TP53 overexpression in recurrent endometrial carcinoma. Gynecol Oncol 2006; 100: 397-404.
15. FIGO. Announcements. FIGO Stages - 1988 Revision. Gynecol Oncol 1989; 35: 125-7.
16. Mattsson K, Pokrovskaja K, Kiss C, et al. Proteins associated with the promyelocytic leukemia gene product (PML)-containing nuclear body move to the nucleolus upon inhibition ofproteasome-dependent protein degradation. Proc Natl Acad Sci USA 2001; 98: 1012-7.
17. Lapach S, Chubenko AV, Babich PN. Statistical Methods in Medico-Biological Studies. Kiev: Morion, 2001.
18. Wang Yu-C, Lin R-K, TanYi-H, et al. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer. J Clin Oncol 2005; 23: 154-64.
19. McAlpine PJ, Shows TB, Boucheix C, et al. The 1991 catalog of mapped genes and the nomenclature committee. Cytogen Cell Gen 1991; 58: 5-102.
20. ink4a in tissue of human endometrial adenocarcinoma. Exp Oncol 2006; 28: 152-5.
21. Hamel NW, Sebo TJ, Wilson TO, et al. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Gynecol Oncol 1996; 62: 192-8.
22. Ioffe OB, Papadimitriou JC, Drachenberg CB. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol 1998; 29: 1150-9.
23. Koul A, Bendahl PO, Borg A, et al. TP53 protein expression analysis by luminometric immunoassay in comparison with gene mutation status and prognostic factors in early stage endometrial cancer. Int J Gynecol Cancer 2002; 12: 362-71.
24. Kounelis S, Kapranos N, Kouri E, et al. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 2000; 13: 379-88.
25. Miller R. True positive vs. false positive staining. In: The Focus Immunohistochemistry. Dallas: ProPath, 2001; 1-2.
26. Soslow RA, Shen PU, Chung MH, Isacson C. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma. Int J Gynecol Pathol 1998; 17: 129-34.
27. Mantovani F, Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 2001; 20: 7874-87.
28. Scheffner M, Whitaker NJ. Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Seminars in cancer biology 2003; 13: 59-67.
29. O'Leary JJ, Landers RJ, Crowley M, et al. Human papillomavirus and mixed epithelial tumors of the endometrium. Hum Pathol 1998; 29: 383-9.
30. Semczuk A, Stenzel A, Baranowski W, et al. Detection of human papillomavirus types 16 and 18 in human neoplastic endometrium: lack of correlation with established prognostic factors. Oncol Rep 2000; 7: 905-10.
31. Staebler A, Sherman ME, Zaino RJ, et al. Hormone receptor immunohistochemistry and human papillomavirus in situ hybridization are useful for distinguishing endocervical and endometrial adenocarcinomas. Am J Surg Pathol 2002; 26: 998-1006.
32. Plunkett M, Brestovac B, Thompson J, et al. The value of HPV DNA typing in the distinction between adenocarcinoma of endocervical and endometrial origin. Pathology 2003; 35: 397-401.
33. Ansari-Lari MA, Staebler A, Zaino RJ, Shah KV, Ronnett BM. Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol 2004; 28: 160-7.
34. Feng YZ, Shiozawa T, Horiuchi A, et al. Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas. Virchows Arch 2005; 447: 816-22.
35. Wei CL, Wu Q, Vega VB, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006; 124: 207-19.
36. Liu W, Konduri SD, Bansal S, et al. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J Biol Chem 2006; 281: 9837-40.
37. Ryan AJ, Susil B, Jobling TW, et al. Endometrial cancer. Cell Tissue Res 2005; 322: 53-61.